Douglas A. Dachille - Mar 14, 2022 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role: Director
Signature: /s/ Brian C. Stephenson, Attorney-in-Fact
Stock symbol: BBIO
Transactions as of: Mar 14, 2022
Transactions value $: $81,934
Form type: 4
Date filed: 3/16/2022, 04:46 PM
Previous filing: Jan 6, 2022
Next filing: Jun 24, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BBIO	Common Stock	Purchase	$81.9K	+10K	+100%	$8.19	20K	Mar 14, 2022	By The Dachille 2012-1 Family Trust	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the weighted average purchase price of the shares purchased from $8.1699 to $8.2084 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions as reported in this footnote.
F2	These shares are owned directly by The Dachille 2012-1 Family Trust for the benefit of the reporting person's children, for which the reporting person's spouse is the trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Content

Represents the weighted average purchase price of the shares purchased from $8.1699 to $8.2084 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions as reported in this footnote.

These shares are owned directly by The Dachille 2012-1 Family Trust for the benefit of the reporting person's children, for which the reporting person's spouse is the trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.